Phreesia, Inc.

Executive summary

Phreesia is a three-segment healthcare technology business — patient intake software, provider-embedded payments, and a point-of-care pharma media network — priced by the public market as if only the first segment existed. The current enterprise value of roughly $730M implies that Network Solutions, the pharma-advertising business that generated $140M of revenue in FY2026 at gross margins plausibly above 65%, is being ascribed zero or modestly negative value. That dislocation, combined with a pharma ad-spend reset, a $110M bridge loan maturing November 2026, and a 21-year-tenured founder-CEO, creates a credible 12–18 month take-private window.

The sum-of-parts distortion

Phreesia reports one consolidated P&L. A segmentation lens changes the picture materially. The Network Solutions business — pharma manufacturers paying to reach patients at the point of care — is a direct analogue to PatientPoint, which Advent International acquired in Q4 2025 for a reported $1.4B+. PatientPoint operates at a similar scale of provider offices (30,000 vs. Phreesia's ~4,700 AHSCs with deeper patient touchpoints per site). A like-for-like multiple applied to Phreesia's Network Solutions revenue implies $550–800M of standalone value. Against a consolidated EV near $730M, the market is implicitly assigning the core Healthcare Services subscription and payments business — growing 14–16% and sitting on $340M of FY2026 revenue — a negative value.

Why the window is open now

1. Pharma ad-cycle trough. FY2027 guidance was reduced in March 2026 on "shorter visibility" from pharma manufacturers. This is a cyclical overlay — IRA drug-pricing pressure, GLP-1 category saturation, and tariff-sensitive consumer exposure — not a structural unwind. POC channel industry spend still grew 16% in 2025 to $1.2B. An acquirer taking private at trough valuation owns the rebound.
2. Capital structure catalyst. Phreesia drew a $110M 364-day bridge loan from Goldman Sachs in November 2025 to fund AccessOne. It matures November 2026. A sponsor-led take-private refinances the bridge inside a broader capital stack; a public-market refi at current trading multiples dilutes optionality.
3. Shareholder patience is finite. HLM Venture Partners (10.69%) has held the position since pre-IPO (IPO July 2019). At 6+ years and a stock price 85% below its 2021 peak, HLM is the most likely catalyst for a strategic review. Fidelity (9.55%), BlackRock (9.09%) and Vanguard (8.30%) provide a concentrated but transaction-rational free-float.
4. Board signal. The November 2024 appointment of Jon Kessler — former HealthEquity CEO, who led that company through its 2014 private-to-public arc and retained significant M&A fluency — is an independent-director addition that typically precedes strategic-alternatives work.

Key takeaways for a prospective strategic or sponsor

• Five credible strategic acquirers — Veeva Systems, athenahealth (Bain/Hellman & Friedman), IQVIA, Doximity, and Veradigm (Vector Capital) — each with a distinct thesis covered in §7.
• Four sponsor theses worth pressure-testing — Thoma Bravo, Vista Equity Partners, Francisco Partners, and Hellman & Friedman. All four have closed healthcare-software take-privates in the last 24 months (§8).
• Precedent multiples in healthcare-software take-privates cluster at 12–15× LTM EBITDA and 2.5–4× revenue. Phreesia currently trades at approximately 7× FY2026 adjusted EBITDA and 1.5× revenue, implying 80–110% premium capacity before multiples exceed precedent (§9–10).
• Key diligence flags: AccessOne integration execution (healthcare RCM is historically messy), pharma ad-cycle duration, founder/co-founder alignment on sale process, Epic MyChart competitive encroachment (§11).

Business overview

Phreesia was founded in 2005 by Chaim Indig (current CEO) and Michael Weintraub (current Founding Chair) with a narrow insight: the paper clipboard at the front desk of a medical office was the highest-friction, lowest-data point in the entire US healthcare experience. Two decades of compounding on that insight have produced a business that sits at the intersection of three very different markets.

The company IPO'd on the NYSE in July 2019 at $18 per share, peaked above $75 in late 2021 on pandemic-era digital-health multiples, and trades at approximately $11 as of April 2026. It reported first-ever GAAP profitability in FY2026 (fiscal year ended January 31, 2026) and generated more than $50M of free cash flow. Headcount is approximately 2,100.

The three-segment architecture

Phreesia's revenue segmentation is the single most important frame for understanding the asset. The three segments are technologically linked (they share the same check-in event, the same patient, the same clinical context) but economically distinct.

FY2026 (year ended January 31, 2026) total revenue $480.6M. Gross-margin ranges are illustrative; Phreesia reports consolidated gross margin (~68% in FY2026) but does not disclose segment-level gross margin. Confidence: Medium — segment revenue disclosed; unit economics derived from management commentary and channel benchmarks.

The network flywheel

The three segments are not independent product lines — they compound. A family-practice provider signs up for Subscription (digital intake replaces paper). Patient check-ins start generating a payments event stream (copays collected through the platform). Phreesia now has a captive, consented, clinically-targeted moment with the patient, which it monetises with pharma sponsors (Network Solutions). Subscription and payments revenue grow with client count and same-store expansion; Network Solutions revenue grows with the same denominator, but at a multiplier.

The unit economics of this flywheel are visible in the revenue-per-AHSC metric. Phreesia reports 4,658 Average Healthcare Services Clients (AHSCs) for Q4 FY2026, generating approximately $27,279 of total revenue per AHSC — up 8% year-over-year. That per-site monetisation rate is materially higher than any pure-intake or pure-scheduling competitor, where benchmark ARPUs land in the $5,000–$12,000 range. The difference is Network Solutions layering on top of the same customer.

Customer base & network scale

Phreesia serves approximately 4,700 healthcare organisations across primary care, specialty care (behavioral health, cardiology, oncology, orthopedics, dermatology among the largest), community health, and federally-qualified health centres. It operates across all 50 US states and Canada, with deepest penetration in primary care and behavioral health. No single client is disclosed as exceeding 5% of revenue; the customer book is structurally diversified.

The AccessOne acquisition (closed November 12, 2025, for approximately $164M) extends the customer base into large US health systems — a segment where AccessOne's patient financing product is already deployed in some of the nation's largest IDNs. For an acquirer, this matters: Phreesia's traditional footprint is mid-market provider groups; AccessOne's is enterprise health systems. The combined customer book spans the full US provider pyramid.

Recent product launches (FY2026)

• Phreesia VoiceAI (November 2025) — AI-powered phone answering for patient calls into practice offices. Addresses a known revenue leak (missed calls, delayed appointment-booking) and creates a new data surface for Network Solutions.
• ProviderConnect (March 2026) — clinician-targeted offering that extends Network Solutions beyond patients to clinical decision points. Opens a second pharma revenue line (HCP-facing rather than DTC).
• AccessOne integration — in progress through FY2027. Key KPI: cross-sell attach of AccessOne patient-financing product into Phreesia's existing 4,700 AHSC base.

Geographic and vertical exposure

Vertical splits are indicative; Phreesia does not formally disclose revenue by medical specialty. Confidence: Low-Medium — triangulated from customer-logo disclosure and public case studies.

Market context & competitive landscape

Phreesia operates across two distinct end-markets — one mature and fragmented (provider workflow software), one in the middle of a structural shift (point-of-care pharma media). The investment thesis for an acquirer turns on which market is doing the valuation work.

Market 1 · Patient intake & provider workflow software

The US patient-intake and engagement software category sits inside a broader healthcare-IT market estimated at $70–85B globally and growing mid-single-digits. The intake-and-engagement slice specifically is estimated at $4–6B annually in the US, growing at low-teens, driven by three forces: (a) the persistent gap between EHR vendors' native patient-facing functionality and what providers and patients actually want, (b) the post-pandemic consumerisation of provider selection and check-in, and (c) reimbursement-adjacent use cases (eligibility verification, prior authorisation capture, consent-management) that monetise through reduced claim denials.

The category is structurally fragmented at the high end and consolidating at the low end. EHR-native patient portals (Epic MyChart, athenahealth, Cerner/Oracle, eClinicalWorks) are free to customers and acceptable to price-sensitive segments. Best-of-breed platforms (Phreesia, Klara/ModMed, Luma Health, Weave, Solutionreach/Rectangle Health, Clearwave, Relatient) compete on workflow depth, integration breadth, and outcome evidence. Phreesia is the category's scale leader on revenue and the only name in the set that has combined a workflow business with a media business.

Scale comparison based on estimated revenue. Confidence: Medium — private-company revenue figures triangulated from press, LinkedIn headcount, and channel checks.

Market 2 · Point-of-care (POC) pharma marketing

The point-of-care pharma marketing channel is the less widely-understood leg of Phreesia's business — and the one where the valuation gap is most acute. POCMA (Point of Care Marketing Association) members reported $1.2B of channel spend in 2025, up 16% year-over-year and growing at a 22% compound rate since 2019. POCMA estimates this captures 80–85% of US channel spend; total US POC pharma marketing is plausibly $1.4–1.6B.

The channel is concentrating structurally. Pharma advertisers are migrating budget from TV and run-of-site digital display into measurable, near-prescription-decision channels. Industry data points: 58% of patients who see POC advertising ask their physician about the advertised treatment; 34% actually receive a prescription for the newly-advertised drug. Veeva Crossix case studies indicate POC represents roughly 14% of total pharma media investment but generates approximately 35% of new-patient starts — a performance multiple that budgets are now chasing.

Confidence: High — POCMA data is the industry reference; network scale triangulated from company disclosures.

The structural tailwinds

• Provider workflow digitisation. The clipboard-to-tablet transition is still less than 50% complete in US ambulatory care. Primary-care greenfield remains. Specialty-care verticals are behind primary care and represent the fastest-growing segment.
• Value-based care monetisation. Eligibility capture, prior-auth triage, and care-gap closure at intake directly reduce claim denials and improve HEDIS scores — monetisable outcomes that Phreesia's platform captures at low marginal cost.
• Pharma channel migration to measurable media. Pharma OOH grew 21% Jan–Aug 2025; run-of-site display fell 22%. POC captures the beneficiaries. Phreesia's ability to measure prescription outcome via downstream payments data is a structural advantage over screen-only networks.
• Consumerisation of patient payments. High-deductible health plans have shifted $500B+ of provider revenue into patient liability. The AccessOne acquisition extends Phreesia into the patient-financing layer that inevitably follows.

The structural headwinds

• Epic MyChart expansion. Epic's patient portal continues to add features (scheduling, check-in, e-consent). For Epic-anchored health systems, MyChart is effectively free. This caps Phreesia's addressable market in the 2,500+ largest US health systems.
• Pharma-cycle exposure (Network Solutions). The Inflation Reduction Act drug-price negotiation, patent-cliff expirations for Humira/Keytruda-class assets, and GLP-1 category saturation have shortened pharma ad-budget visibility. FY2027 guidance was materially cut on this basis. Duration risk of this headwind is the single biggest debate on the name.
• EHR-vendor bundling. athenahealth, eClinicalWorks, NextGen, and ModMed all continue to build or acquire intake functionality. Phreesia's ability to win new logos increasingly depends on best-of-breed workflow differentiation and the Network Solutions cross-sell rather than point-product intake superiority.
• Tech-giant entry risk. Amazon (One Medical), Google (Verily), and Apple (Health) have periodic ambitions in provider-facing workflow. None is imminent, but any of the three represents a disruptive competitor that a sponsor thesis must address.

Financial profile & segment economics

Phreesia's headline financials understate the quality of the asset at the segment level. Consolidated FY2026 adjusted EBITDA margin of 21% is respectable for mid-stage healthcare software but not differentiated. Segment-level unit economics, where derivable, are markedly better — with Network Solutions in particular carrying the margin profile of a scaled digital media business trapped inside a provider-software wrapper.

Revenue trajectory & profitability inflection

FY27 guidance reduced from initial range in March 2026 on pharma softness. Confidence: High for reported periods; Medium for FY27 given the recent guide cut.

Segment-level unit economics (triangulated)

Phreesia reports consolidated non-GAAP gross margin (~68% in FY2026) and segment-level revenue only. It does not disclose segment gross margin, EBITDA, or operating income. The estimates below are triangulated from three inputs per segment: (i) peer-company gross margin for the business model most closely matching the segment, (ii) Phreesia management commentary in earnings calls, and (iii) public filings (10-K, 10-Q) where segment-cost disclosure is partial. Each row below identifies the three benchmark comparables that anchor the estimate.

Confidence: Medium — three triangulation benchmarks per segment. A full-diligence exercise would replace this with management-provided segment financials. The central analytical claim — that Network Solutions carries a materially above-blended gross margin — is robust across all reasonable benchmark ranges, as Doximity, PatientPoint, and Health Monitor all sit above the Payments-segment gross margin floor.

Why the segment mix matters for EBITDA drop-through

Subscription revenue carries meaningful implementation cost at customer acquisition (historical Phreesia LTV/CAC disclosure implies ~12–18 months to per-AHSC contribution neutrality). Network Solutions revenue carries essentially no variable customer-acquisition cost — pharma advertisers buy through annual brand-team budget cycles with low-effort sales motions relative to the SaaS seat-sell. The practical consequence: an incremental dollar of Network Solutions revenue drops through to consolidated EBITDA at roughly 2× the rate of an incremental Subscription dollar. This is the core reason why the consolidated 21% EBITDA margin understates the asset's underlying margin profile — Network Solutions is doing a disproportionate share of EBITDA generation on a disproportionately small share of revenue.

Capital structure & the bridge-loan catalyst

Prior to the AccessOne acquisition, Phreesia operated with approximately $90M of cash and negligible long-term debt — an unusually clean balance sheet for a mid-cap SaaS name. The AccessOne transaction (approximately $164M consideration) was funded with $50M of cash on hand plus a $110M 364-day secured bridge loan led by Goldman Sachs Bank USA, which matures November 11, 2026.

The bridge is a timing artefact, not a financing constraint — Phreesia can plausibly refinance into a term loan on reasonable terms. But the maturity date is meaningful for M&A timing. A term-loan refinancing locks in capital costs for three-to-five years and removes the bridge as a negotiating lever. A strategic-alternatives process timed to conclude before the November 2026 refinancing allows the capital-structure decision to be made inside a broader transaction envelope, where a take-private sponsor can put in its own capital stack.

Free cash flow & working capital

Phreesia generated approximately $50M of free cash flow in FY2026, a meaningful inflection from $20M+ of cash burn as recently as FY2024. FCF conversion (FCF / adj EBITDA) of approximately 50% is lower than best-in-class software comparables (70–80%) because of capitalised software development and implementation capex. For a sponsor underwriting a leveraged take-private, FCF conversion would be the single most important modelling question — a range of 45–65% is defensible; the higher end is achievable through cap-ex discipline and payment-term rationalisation.

M&A track record

Phreesia has been a relatively disciplined acquirer, with a measured cadence over its post-IPO history and one step-change transaction (AccessOne) that shifts the capital-structure picture.

Confidence: High — both transactions disclosed publicly with SEC 8-K filings.

AccessOne — the strategic anchor acquisition

AccessOne is a patient-financing platform that provides flexible payment plans to patients of large US health systems. It works at the opposite end of the provider-size spectrum from Phreesia's traditional mid-market ambulatory base — AccessOne's reference clients include multiple billion-dollar-plus integrated delivery networks. The strategic logic is three-fold: (a) Phreesia already collects patients' immediate copays and deductibles through its platform; AccessOne addresses what happens when the balance is too large for immediate settlement, closing a workflow gap; (b) AccessOne brings enterprise-scale provider relationships that Phreesia historically lacked; (c) the financial profile is attractive — $35M annualised revenue and $11M annualised EBITDA (a 31% margin, well above Phreesia's blended rate).

Key diligence items for any acquirer of Phreesia in the current window: (i) AccessOne revenue retention post-transaction (health-system procurement often tests vendor continuity at change-of-control); (ii) cross-sell execution of AccessOne into Phreesia's ambulatory base; (iii) integration-cost run-rate versus announced synergies; (iv) regulatory exposure — patient-financing products are subject to state-level consumer-lending rules and CFPB oversight, adding a compliance surface Phreesia historically did not have.

Ownership, governance & free float

Phreesia's ownership structure is highly concentrated in institutional holders, with a small but symbolically significant insider position and one legacy venture-capital holder whose liquidity profile is increasingly strained. Single-class common stock means the capital structure does not create any founder-lock dynamic.

Top holders

Figures as of most recent 13F disclosure window (Q1 2026). Confidence: High — sourced from SEC 13F and proxy disclosures.

Board composition & the Kessler signal

The board consists of seven directors, six of whom are independent. The M&A-relevant addition is Jon Kessler (joined November 2024), founding CEO of HealthEquity. Kessler ran HealthEquity through its 2014 IPO and subsequent roll-up phase, stepping down as CEO in 2023. The profile — scaled healthcare-tech operator with deep public-market M&A fluency — is the type of independent director whose appointment typically precedes a strategic-alternatives conversation, though there is no public evidence that such a conversation is formally underway.

Michael Weintraub, the Founding Chair and Indig's co-founder, remains on the board. Any transaction requires both Indig and Weintraub to endorse it; their alignment is the single highest-leverage diligence question a prospective acquirer should answer via informal dialogue (or through advisor channels) before committing to a formal approach.

Equity overhang & tender mechanics

Phreesia has no dual-class structure, no staggered board, and no classified director terms that would impede a standard take-private. The company has a poison-pill shareholder-rights plan that is typical for a mid-cap; it would be disabled in the context of a negotiated board-endorsed transaction. Delaware incorporation provides the standard governance framework. No material change-of-control severance cliffs exist outside the typical CEO/C-suite employment agreements.

Strategic acquirer analysis

Phreesia is an unusually multi-directional strategic target because its three segments map to three different acquirer archetypes. A workflow-software buyer will value Subscription and Payments. A pharma-services or digital-media buyer will value Network Solutions. An EHR platform will value the combined provider-relationship book. This section identifies five credible strategics and assesses each on fit, capacity, and transaction probability.

7.1 · Veeva Systems (NYSE: VEEV)

Veeva Crossix — the company's DTC and HCP measurement platform acquired in 2019 for $430M — sits on approximately 330 million US patient lives' worth of claims, Rx, and clinical data and sells measurement and targeting services to pharma manufacturers. The structural gap in the Crossix value proposition is placement: Veeva can measure and optimise pharma campaigns but does not own the consumer-facing inventory where those campaigns run. PatientPoint's sale to Advent in Q4 2025 explicitly removed the largest third-party POC placement asset from the market. Phreesia Network Solutions is the second-largest remaining POC asset of meaningful scale, and the only one with measurement-by-design architecture (consented, clinically-contextualised, prescription-outcome trackable via downstream claims).

A Veeva acquisition of Phreesia would carry two integration headaches the acquirer would have to underwrite: (i) Subscription and Payments are businesses Veeva has no competence in running — a divestiture to a sponsor or workflow-software strategic at close is plausible; (ii) the post-deal pharma customer base reaction to Phreesia being owned by Veeva — pharma customers who currently use both independently may resist consolidation. A cleaner structural answer may be a Veeva-led carve-out of Network Solutions at transaction close rather than a whole-company acquisition.

Deal rationale for a banker's pitch to Veeva. Veeva has signalled market-leadership ambitions in life-sciences commercial; Network Solutions is the highest-ROI placement asset now that PatientPoint is captive to Advent. Acquiring Phreesia pre-empts PatientPoint-Advent from becoming the consolidated market; it also insulates Veeva from Salesforce (which owns Exact Target/Pardot and has periodic signals on life-sciences marketing).

7.2 · athenahealth (private; Bain Capital + Hellman & Friedman)

Bain Capital and Hellman & Friedman took athenahealth private in 2022 at approximately $17B. The thesis under private ownership has been platform rationalisation, margin expansion, and bolt-on acquisitions that extend athenahealth into adjacent provider workflow. Phreesia fits that frame — though at $1B+ it sits near the top of what athenahealth would typically absorb.

Two wrinkles. First, athenahealth already has native patient-check-in functionality inside its ambulatory EHR; a Phreesia acquisition would require a product-overlap decision. The Network Solutions piece, however, is a clean incremental asset. Second, Hellman & Friedman is a credible sponsor-acquirer on its own (see §8); the firm could finance a whole-company take-private outside the athenahealth portfolio and integrate post-transaction. Of the two paths, the direct athenahealth bolt-on is less likely than an H&F-led take-private with a possible post-transaction integration.

7.3 · IQVIA Holdings (NYSE: IQV)

IQVIA is the world's largest clinical-trial and pharma-services company. Its commercial-solutions segment (~$3B revenue) competes with Veeva Crossix at the measurement and targeting layer. Like Veeva, IQVIA lacks a direct-to-consumer placement asset at scale. Unlike Veeva, IQVIA's cultural M&A appetite skews toward data, services, and CRO acquisitions — a provider-facing SaaS platform would sit awkwardly. A Network Solutions carve-out is more plausible than a whole-company acquisition.

The August 2025 IQVIA–Veeva settlement and partnership resolved a long-running commercial-data dispute and reshapes the competitive dynamic. IQVIA has a marginally stronger case now to acquire a complementary placement asset than it did 18 months ago; the partnership reduces the risk that a Phreesia acquisition would be treated as hostile by Veeva.

7.4 · Doximity (NYSE: DOCS)

Doximity operates the physician-facing digital media asset that mirrors Phreesia's patient-facing one. The combined entity would deliver pharma advertisers a full-funnel solution (HCP targeting and patient targeting) unique in the market. Strategically compelling. Operationally and culturally, the fit is weaker — Doximity has been a disciplined, highly-profitable organic operator with essentially no M&A history. Including as a completeness check rather than a likely buyer.

7.5 · Veradigm (private; Vector Capital)

Veradigm (formerly Allscripts) was acquired by Vector Capital from public markets in 2024. The resulting private company has a similar structural shape to Phreesia — ambulatory EHR and practice-management workflow on one side, a Life Sciences data monetisation business on the other. A combined Veradigm-Phreesia entity would rival athenahealth in ambulatory scale and would consolidate two of the three remaining POC pharma-media platforms. Vector Capital may prefer to monetise Veradigm before taking on an additional large transaction, but a sponsor-club structure (Vector + a larger sponsor such as Thoma Bravo) is a credible path.

Strategic-fit summary matrix

Probability scores are subjective assessments on a 0–5 scale reflecting combined fit, capacity, and observable M&A cadence. Premium ranges are referenced to the $11.20 April-2026 share price. Confidence: Medium.

Financial sponsor analysis

The financial-sponsor landscape for Phreesia is shallow and unambiguous — healthcare-software take-privates at this size-point cluster at five firms, four of which have closed a directly-comparable transaction in the last 24 months. Sponsor-led pathways are more probable than a strategic acquisition in the 12–18 month window.

8.1 · Thoma Bravo

Thoma Bravo is the single most predictable sponsor acquirer for Phreesia. The NextGen Healthcare playbook is a direct template: a mid-cap healthcare-SaaS business with pedigreed but exhausted public shareholders, trading below peer multiples, acquired at an ~13× LTM EBITDA take-out and subsequently repositioned. The May 2025 Madison Dearborn Partners equity-recap into NextGen demonstrates Thoma Bravo's willingness to structure syndicated holds at this size-point and sector.

The one question mark is whether Thoma Bravo would want two healthcare-SaaS names (NextGen, Phreesia) simultaneously held. Portfolio-management considerations make this possible but not automatic. An alternative read: Thoma Bravo's appetite is sufficient that a Phreesia mandate could be worked under a parallel-hold structure with different fund vintages.

8.2 · Vista Equity Partners

Vista's acquisition of Model N (life-sciences revenue management software) in 2024 at approximately 18× LTM EBITDA set the benchmark for SaaS-premium valuation at the time. Vista's operational playbook — Vista Value Creation methodology, centralised FP&A, best-practice pricing optimisation — is the sharpest in the industry and would extract meaningful value from Phreesia's current go-to-market architecture.

The relevant question is whether Vista would be deterred by Network Solutions (a media business, outside Vista's classic vertical-SaaS sweet spot). Our view: Vista is increasingly comfortable with healthcare-adjacent assets (Mindbody, Ping Identity, ~Duck Creek, Model N) that have non-SaaS revenue components; a Network Solutions carve-out or separate optimisation thesis would address this.

8.3 · Francisco Partners

Francisco Partners completed the $1B leveraged buyout of AdvancedMD in December 2024 — a direct template for a Phreesia transaction. AdvancedMD combines EHR, practice management, patient engagement, and RCM; the acquisition cemented Francisco's position as a systematic consolidator of provider-facing healthcare-IT. Phreesia is both a scale-larger target and a conceptual extension of the thesis, bringing the point-of-care media leg that AdvancedMD does not have.

8.4 · Hellman & Friedman

Hellman & Friedman co-owns athenahealth with Bain Capital and has a long history in healthcare technology (Kronos, AlixPartners-adjacent healthcare operations, Grocery Outlet – not healthcare but illustrates deal-structure range). A Phreesia acquisition under H&F auspices could operate either as a standalone platform or as an athenahealth bolt-on; the former is more probable given the mid-cycle timing of the athenahealth hold.

8.5 · Other credible sponsors (ranked lower)

• Clayton Dubilier & Rice — healthcare-services focus; ModMed ownership creates potential complementary-platform logic. Moderate probability.
• KKR — healthcare-SaaS capable but has not been active in this specific pocket recently. Lower probability.
• Blackstone — healthcare platform (Ancestry-adjacent, Sphera) experience but cadence at this size-point is slower. Lower probability.
• Bain Capital (separate from athenahealth vehicle) — has healthcare software appetite; ownership overlap with athenahealth creates complexity. Moderate probability.

Comparable transactions

Three comp sets are relevant to a Phreesia valuation: (a) public trading comparables in healthcare technology, which anchor current-market multiples, (b) healthcare-software take-privates, which anchor the Subscription and Payments segments at transaction multiples, and (c) point-of-care pharma-media transactions, which anchor the Network Solutions segment. Blended valuation requires triangulating all three.

Comp set A — Public trading comparables

The table below captures the current public-market trading of healthcare-technology companies that bracket Phreesia across three axes: scale, business-model composition, and growth-profitability mix. Phreesia's own trading multiples are included at the bottom for direct comparison.

Multiples as of April 2026 trading; LTM revenue on most-recent-reported basis. Excludes comps without meaningful EBITDA (Weave). Confidence: High on listed multiples — triangulated from company disclosures and Bloomberg-equivalent data.

Comp set B — Healthcare-software take-privates

Multiples are approximate and referenced to LTM or forward-year figures as disclosed. Olo is not a pure-healthcare comp but is included for multiples-benchmark completeness given Thoma Bravo involvement. Confidence: High on headline deal values; Medium on multiples given inconsistent disclosure.

Comp set C — Point-of-care pharma-media transactions

Confidence: Medium — POC private-market transaction data is sparse and frequently undisclosed.

Precedent-multiple summary

Valuation framework

Phreesia supports three defensible valuation frames: a consolidated EV/EBITDA approach (the simplest), a sum-of-parts bridge (the most accretive to a bidder), and a take-private premium-to-reference approach (the most useful for process design). Each points to a transaction range materially above current trading.

Reference price cascade

Phreesia shares have traded across a wide range over the past 12 months on two successive guidance resets (Q3 FY26 on December 8, 2025, which introduced a softer-than-consensus FY27 outlook and triggered a −23% single-session reaction; and Q4 FY26 on March 30, 2026, which reduced the FY27 revenue guide a second time from $545–559M to $510–520M). Any premium-to-reference analysis therefore needs to be expressed against multiple anchor points, not one. Delaware fiduciary-duty case law customarily treats the 90-day VWAP as the primary reference for a board evaluating a take-private; the unaffected price is more straightforward in cases where a strategic-alternatives process has been publicly announced.

Prices approximate, triangulated from NYSE trade data. Two-step reset: Dec 8 2025 (−23% single session on Q3 print + initial FY27 guide), then March 30 2026 (additional reduction of FY27 guide). Confidence: Medium.

Sell-side consensus context

Phreesia is covered by 15 sell-side analysts. Consensus was a "Strong Buy" composite pre-December 2025 with a 12-month target-price average of approximately $31. Post-March-2026 guide cut, median target has compressed to approximately $25, with a wide dispersion (KeyBanc at $12, Piper Sandler cut to $23 from $34, Canaccord cut to $22 from $38, others at $28–35). The stock trades at a roughly 55% discount to the post-reset median target and a roughly 65% discount to the pre-reset target — an unusually wide gap that, absent a fundamental thesis change, creates the valuation opening for a strategic-alternatives process.

Confidence: Medium — specific analyst names verified for Piper, Canaccord, KeyBanc via published research; other firm-analyst assignments indicative.

Key valuation inputs

FY27 guide midpoint revised downward by approximately 7% between December 2025 and March 2026. Confidence: High on reported figures; Medium on net-debt mark.

Current trading multiples

Frame 1 · Consolidated EV/EBITDA bridge

Applying the precedent-median 14× EV/EBITDA multiple to FY27E adjusted EBITDA of $125M (post-March-2026 reset midpoint) implies an enterprise value of approximately $1.75B — a 140% premium to current EV. A more conservative 11× multiple implies $1.38B EV (89% premium). A 9× multiple — below all precedent — implies $1.13B EV (54% premium). The range of 9–14× brackets plausible take-out EV between $1.13B and $1.75B.

Frame 2 · Sum-of-parts bridge

Applying segment-appropriate multiples to each of Phreesia's three businesses yields the following:

Multiples applied on FY26 revenue basis. The single-buyer underwrite adjustment reflects three specific frictions, not a generic "conglomerate discount": (a) no single buyer in the strategic universe optimally values all three segments — a Veeva would pay premium multiples for Network Solutions but a discount for Subscription it does not know how to run; (b) a sponsor taking all three on prices in a timing penalty for eventual Network Solutions carve-out optionality; (c) Payments is a routing-economics business that a buyer outside of payments rails will underprice relative to a Waystar or Shift4. The 8–15% range is anchored in the empirical spread between sum-of-parts analyst estimates and actual conglomerate transaction values observed in the Duff & Phelps / Kroll multi-segment transaction dataset (2020–2024, median ~12%). Confidence: Medium.

Frame 3 · Premium-to-reference (market process design)

The table below is anchored to the 90-day VWAP of approximately $12.25, the reference most likely to be used by the Phreesia board and its financial advisors in evaluating any offer. The right-most columns show the equivalent premium to the pre-December-2025 close of $15.75 (the last trading day before the first guide reset), which is the reference an acquirer should anticipate being raised by a board seeking to demonstrate a negotiation outcome above "normalised" market levels.

EV/EBITDA calculated against FY27E midpoint of $125M (post-reset). Premium references: spot $11.20, 30-day VWAP ~$11.45, 90-day VWAP ~$12.25. Confidence: Medium.

Three observations frame how a buyer should read this table. First, the post-reset dislocation means the "opening-bid" offer of $19.50 is only +24% above the pre-reset close of $15.75 — i.e., an acquirer effectively captures the guide-cut-driven air pocket as a pricing discount. Second, the likely-clearing price of $22.00 sits below both the pre-reset consensus target ($31) and the post-reset consensus target ($25), which means Phreesia's sell-side coverage is explicitly signalling that a takeout in the low-$20s is below the public-market path. Third, a competitive process that pushes into the mid-to-high $20s is defensibly priced against NextGen-precedent multiples without requiring aggressive sum-of-parts credit — the $25–28 range is inside peer precedent, not above it.

Key risks & diligence flags

The diligence surface on Phreesia is larger than a single-segment SaaS target because three distinct business models converge inside one P&L. A prospective acquirer should pressure-test each of the following before committing to a binding offer.

Pharma ad-cycle duration (highest-impact risk)

The March 2026 FY27 guidance cut cited "shorter visibility" from pharma manufacturers. A sponsor underwriting an aggressive take-out multiple needs a defensible view on whether pharma marketing budgets normalise within 12–18 months (cyclical) or whether the softness reflects a structural reset (IRA drug-pricing suppression, post-GLP-1 ad-spend compression, generic-biologic patent cliff). Our base case is cyclical; the POC channel grew 16% in calendar 2025 even as Phreesia's Network Solutions decelerated, implying share-shift not channel collapse. Diligence must validate this via direct pharma-brand-team conversations.

AccessOne integration execution

Healthcare RCM integrations have a well-earned reputation for execution friction. Key sub-risks: (i) revenue retention on top-5 AccessOne accounts at change-of-control; (ii) regulatory compliance surface (state consumer-lending, CFPB) that Phreesia historically did not carry; (iii) synergy realisation on cross-sell to ambulatory-sized clients who may not have sufficient patient-financing need to justify the product. A three-month deep-dive with AccessOne reference customers is the highest-leverage single diligence expenditure.

Founder-CEO alignment

Chaim Indig has run Phreesia for 21 years. A transaction requires his personal endorsement. Secondary questions: (i) does Indig want to continue to run the business under private ownership (common and preferred for sponsors), or does he want a clean exit; (ii) what is his personal compensation appetite; (iii) is Michael Weintraub (co-founder, Founding Chair) aligned. Private advisory conversations with each ahead of any formal approach carry high marginal value.

Epic MyChart competitive encroachment

Epic's patient portal keeps adding functionality at zero incremental customer cost. For the ~2,500 largest US health systems that are Epic-anchored, Phreesia's addressable market is structurally capped. This is a known, slow-moving headwind rather than a sudden threat, but it materially affects the multi-year growth bridge. Diligence should quantify Phreesia's revenue concentration in non-Epic-anchored clients versus Epic-anchored ones.

Customer concentration in Network Solutions

While Phreesia does not disclose client concentration, the Network Solutions business by industry logic concentrates on a small number of large pharma advertisers per year. The top 10 pharma manufacturers represent 60%+ of US brand-drug advertising spend. Loss of two or three large brand accounts (driven by indication-specific ad-cycle timing or agency rotation) could drive a larger revenue swing than an equivalent Subscription-segment loss. Diligence must review the top 10 Network Solutions customer contracts, their historical volatility, and renewal economics.

Regulatory — patient data & consent

Phreesia operates under HIPAA as a Business Associate and additionally triggers state-level privacy regimes (California CPRA, Washington MHMDA, emerging state laws). Network Solutions in particular depends on patient consent to serve pharma content. Any tightening of federal or state rules on targeted health-adjacent advertising — or on the scope of Business-Associate data use for commercial purposes — would compress the Network Solutions revenue profile. Diligence should include a specialist health-privacy legal review.

Tech-giant entry risk

Amazon (One Medical), Google (Verily, and the 2026 Fitbit-adjacent data initiatives), and Apple (HealthKit) have ambitions in healthcare workflow and patient engagement. None is an imminent Phreesia competitor, but any of the three could reshape the addressable market over a 5–7 year hold. A sponsor's exit-underwrite must address this; diligence should assess Phreesia's strategic-partnership posture with each of the three.

Bridge-loan refinancing risk (transient)

The $110M Goldman bridge loan matures November 2026. Absent a strategic transaction, this refinances into a term loan — a routine exercise. The risk in the context of M&A is timing, not credit: a transaction that slips beyond the refi window loses a clean capital-structure reset opportunity.

Key-person dependencies

Beyond Indig, Evan Roberts (COO, board member) and the long-tenured senior sales leadership represent material key-person risk. Standard diligence on employment agreements, restrictive covenants, and retention structures applies.

Litigation & regulatory history

Phreesia is not subject to any material publicly-disclosed litigation at the time of this memo. Standard diligence on SEC correspondence, state AG inquiries, and putative class actions is nonetheless prudent.

Conclusion & recommendations

Phreesia is a credible mid-cap healthcare-technology take-private target in the next 12–18 months. The combination of a sum-of-parts dislocation, a pharma-cycle trough, a capital-structure catalyst, and an ageing shareholder base creates a narrower window than the average mid-cap screen would suggest. A transaction is not inevitable, but the asset is plausibly in-play — and the window closes as soon as the bridge is refinanced, the pharma cycle normalises, or HLM Venture Partners transacts its stake via a secondary pathway.

For a strategic

Veeva Systems is the most commercially-compelling whole-company acquirer; athenahealth (via Hellman & Friedman) is the most structurally-fitted. A strategic approach should begin with an advisor-channel test of Veeva's appetite, in parallel with a direct relationship-audit of Hellman & Friedman's healthcare-software team. A whole-company strategic acquisition of Phreesia requires either (a) a multi-year commercial-media thesis that justifies $25+ per share, or (b) a post-close carve-out of Network Solutions to monetise the non-core asset.

For a sponsor

Thoma Bravo is the base-case sponsor; Vista, Francisco, and Hellman & Friedman are credible alternatives. A take-private thesis centres on (a) margin expansion to 28–32% blended adjusted EBITDA over three years, (b) accelerated Network Solutions investment outside public-market scrutiny of pharma-cycle volatility, (c) optional carve-out of Network Solutions at year 3–4 to a pharma-media consolidator (Advent/PatientPoint, Veeva, IQVIA) at premium segment multiples, and (d) capital-structure optimisation via refinancing of the AccessOne bridge into a term-loan facility at deal close.

Recommended next steps for any prospective acquirer

1. Commission a 40–60 page full due-diligence memo extending this framework, including: segment-level cohort analysis, Network Solutions top-10 customer contract review, AccessOne reference-customer diligence, and a health-privacy regulatory review.
2. Secure informal dialogue — through advisor channels, not direct — with HLM Venture Partners. Their posture on a specific price range is the single highest-value diligence input. At a 60-day horizon, also seek advisor-channel dialogue with Chaim Indig's and Michael Weintraub's personal advisors to establish rollover appetite.
3. Commission a specialist POC pharma-media market study to independently validate (a) the cyclical-versus-structural thesis on the FY27 guide cut and (b) the valuation premium justified by Network Solutions on a standalone basis.
4. Model a dual-path bid: solo take-private versus sponsor-vs-strategic tension. Premium-to-reference analysis suggests the negotiated outcome lands in the $19–24 range depending on process structure.
5. If proceeding, structure the transaction timing to close before November 2026 in order to capture the bridge-loan-refinancing optimisation. An announcement by Q2 calendar 2026 is the operationally-consistent target.